Generic, brand-name multiple sclerosis drugs may produce varied effects
A study led by UTSW researchers found that patients with multiple sclerosis (MS) taking generic versions of three commonly prescribed oral therapies had greater variability in blood proteins associated with MS disease activity than patients taking brand-name versions of the drugs.
A study conducted by researchers at the University of Texas Southwestern Medical School has revealed that generic versions of three widely used oral multiple sclerosis (MS) treatments may lead to more variable blood protein profiles compared to their brand-name counterparts. Analyzing data from 1,124 MS patients, the researchers discovered that generic forms of dimethyl fumarate, fingolimod, and teriflunomide were associated with less consistent biomarker patterns, which could indicate differences in drug exposure and disease control.
While the study did not examine clinical outcomes such as relapse rates or disability progression, the findings raise questions about whether such biomarker variations could impact treatment consistency. The authors caution that more research is needed to determine if these biomarker differences translate into real-world variations in patient outcomes and treatment effectiveness.
Written by urgent.news from Medical Xpress's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
